Industry: Small-molecule therapeutics
Nox2 is developing a new drug to treat asthma and other inflammatory lung diseases. The company is exploring small-molecule therapeutics that inhibit myleperoxidase, or Nox2. The inhibitors reduce levels of reactive oxygen in cells and tissue.
The company’s lead molecule for drug discovery is a sub-micromolar inhibitor that has shown to be effective in animal models of lung inflammation. In vitro tests on this molecule have demonstrated good results.
The asthma therapy market exceeds $15 billion annually, and a new first-in-class drug would likely capture a significant share of this market. Nox2’s therapy may also address other inflammatory conditions, such as Acute Respiratory Distress Syndrome and Chronic Obstructive Pulmonary Disease, for which current treatments are inadequate.